Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.23
(-4.17%)
CAD 0.23
(-4.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.3 Million CAD | -12.98% |
| 2022 | -3.81 Million CAD | 69.62% |
| 2021 | -12.54 Million CAD | -414.23% |
| 2020 | -2.44 Million CAD | 70.11% |
| 2019 | -8.16 Million CAD | 28.38% |
| 2018 | -11.39 Million CAD | -22660.73% |
| 2017 | -50.07 Thousand CAD | -6.33% |
| 2016 | -47.09 Thousand CAD | 8.98% |
| 2015 | -51.74 Thousand CAD | -169.47% |
| 2014 | -19.2 Thousand CAD | 1.47% |
| 2013 | -19.48 Thousand CAD | 89.09% |
| 2012 | -178.54 Thousand CAD | -163.66% |
| 2011 | -67.72 Thousand CAD | 15.3% |
| 2010 | -79.95 Thousand CAD | -1074.96% |
| 2009 | -6805.00 CAD | -101.39% |
| 2008 | -3379.00 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.09 Million CAD | 12.61% |
| 2024 Q1 | -1.25 Million CAD | 38.74% |
| 2023 Q3 | -981.07 Thousand CAD | -34.27% |
| 2023 FY | -4.3 Million CAD | -12.98% |
| 2023 Q1 | -566.88 Thousand CAD | 60.81% |
| 2023 Q2 | -730.68 Thousand CAD | -28.9% |
| 2023 Q4 | -2.05 Million CAD | -109.37% |
| 2022 Q4 | -1.44 Million CAD | -147.91% |
| 2022 Q1 | -1.03 Million CAD | 90.85% |
| 2022 Q2 | -914.52 Thousand CAD | 12.0% |
| 2022 FY | -3.81 Million CAD | 69.62% |
| 2022 Q3 | -583.5 Thousand CAD | 36.2% |
| 2021 FY | -12.54 Million CAD | -414.23% |
| 2021 Q1 | 128.62 Thousand CAD | 115.16% |
| 2021 Q2 | -539.43 Thousand CAD | -519.4% |
| 2021 Q3 | -790.75 Thousand CAD | -46.59% |
| 2021 Q4 | -11.36 Million CAD | -1336.89% |
| 2020 FY | -2.44 Million CAD | 70.11% |
| 2020 Q2 | -442.11 Thousand CAD | 10.73% |
| 2020 Q3 | -511.8 Thousand CAD | -15.76% |
| 2020 Q4 | -848.47 Thousand CAD | -65.78% |
| 2020 Q1 | -495.24 Thousand CAD | 48.99% |
| 2019 FY | -8.16 Million CAD | 28.38% |
| 2019 Q4 | -970.79 Thousand CAD | 67.84% |
| 2019 Q1 | -3.07 Million CAD | 67.96% |
| 2019 Q3 | -3.01 Million CAD | -234.39% |
| 2019 Q2 | -902.66 Thousand CAD | 70.62% |
| 2018 Q2 | -504.32 Thousand CAD | -68.94% |
| 2018 Q1 | -298.51 Thousand CAD | 75.61% |
| 2018 FY | -11.39 Million CAD | -22660.73% |
| 2018 Q3 | -1 Million CAD | -99.46% |
| 2018 Q4 | -9.58 Million CAD | -853.32% |
| 2017 Q2 | -26.53 Thousand CAD | -311.86% |
| 2017 Q1 | -6442.00 CAD | -60.45% |
| 2017 Q4 | -1.22 Million CAD | -6193.92% |
| 2017 Q3 | -19.44 Thousand CAD | 26.71% |
| 2017 FY | -50.07 Thousand CAD | -6.33% |
| 2016 Q2 | -16.07 Thousand CAD | -744.33% |
| 2016 FY | -47.09 Thousand CAD | 8.98% |
| 2016 Q3 | -13.09 Thousand CAD | 18.57% |
| 2016 Q4 | -4015.00 CAD | 69.33% |
| 2016 Q1 | -1904.00 CAD | 88.86% |
| 2015 Q2 | -14.34 Thousand CAD | -64.82% |
| 2015 Q4 | -17.09 Thousand CAD | -42.12% |
| 2015 FY | -51.74 Thousand CAD | -169.47% |
| 2015 Q3 | -12.02 Thousand CAD | 16.14% |
| 2015 Q1 | -8701.00 CAD | -9.3% |
| 2014 Q4 | -7961.00 CAD | 61.62% |
| 2014 Q1 | -33.46 Thousand CAD | -308.35% |
| 2014 FY | -19.2 Thousand CAD | 1.47% |
| 2014 Q3 | -20.74 Thousand CAD | -175.31% |
| 2014 Q2 | 27.54 Thousand CAD | 182.3% |
| 2013 FY | -19.48 Thousand CAD | 89.09% |
| 2013 Q4 | -8195.00 CAD | -61.16% |
| 2013 Q3 | -5085.00 CAD | -21.3% |
| 2013 Q2 | -4192.00 CAD | -66.75% |
| 2013 Q1 | -2514.00 CAD | 74.14% |
| 2012 Q1 | -32.98 Thousand CAD | -94.83% |
| 2012 Q4 | -9723.00 CAD | -217.85% |
| 2012 Q2 | -123.53 Thousand CAD | -274.54% |
| 2012 FY | -178.54 Thousand CAD | -163.66% |
| 2012 Q3 | -3059.00 CAD | 97.52% |
| 2011 Q2 | -36.89 Thousand CAD | -386.65% |
| 2011 Q3 | -5105.00 CAD | 86.16% |
| 2011 Q4 | -16.92 Thousand CAD | -231.62% |
| 2011 FY | -67.72 Thousand CAD | 15.3% |
| 2011 Q1 | -7582.00 CAD | 38.6% |
| 2010 Q2 | -14.2 Thousand CAD | -101.53% |
| 2010 Q1 | -7050.00 CAD | 86.91% |
| 2010 FY | -79.95 Thousand CAD | -1074.96% |
| 2010 Q4 | -12.34 Thousand CAD | -13.39% |
| 2010 Q3 | -10.89 Thousand CAD | 23.35% |
| 2009 Q3 | -4886.00 CAD | -142.0% |
| 2009 FY | -6805.00 CAD | -101.39% |
| 2009 Q1 | -1225.00 CAD | 40.1% |
| 2009 Q4 | -53.86 Thousand CAD | -1002.37% |
| 2009 Q2 | -2019.00 CAD | -64.82% |
| 2008 Q3 | -4516.00 CAD | 0.0% |
| 2008 Q4 | -2045.00 CAD | 54.72% |
| 2008 FY | -3379.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -6.78 Million CAD | 36.494% |
| Asep Medical Holdings Inc | -8.22 Million CAD | 47.656% |
| BetterLife Pharma Inc. | -2.88 Million CAD | -49.064% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 43.979% |
| ChitogenX Inc. | -1.55 Million CAD | -177.124% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 67.358% |
| Entheon Biomedical Corp. | -300 Thousand CAD | -1335.495% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | 17.449% |
| Glow Lifetech Corp. | -1.64 Million CAD | -161.696% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | -396.305% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | -452.248% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | -1167.184% |
| MYND Life Sciences Inc. | -1.51 Million CAD | -183.722% |
| Nova Mentis Life Science Corp. | -1.22 Million CAD | -251.717% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | -38.235% |
| PreveCeutical Medical Inc. | -1.27 Million CAD | -237.905% |
| Telescope Innovations Corp. | -5.72 Million CAD | 24.807% |